Vanta Bioscience Ltd (VANTABIO) — shareholding pattern, promoter holding, financials and share price
About Vanta Bioscience Ltd (VANTABIO)
Vanta Bioscience Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as VANTABIO and on the BSE under scrip code 540729. Its ISIN is INE695X01011.
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]
Vanta Bioscience Limited specializes in preclinical activities, particularly in toxicology and safety assessments. It operates GLP-certified facilities delivering services to India and globally.
Founded in 2016, Vanta Bioscience offers risk assessment for chemical safety, catering to pharmaceuticals, cosmetics, and agrochemicals industries.
Listed peers in Healthcare Research, Analytics & Technology: Bilcare Ltd, Jeevan Scientific Technology Ltd, Globalspace Technologies Ltd, Novelix Pharmaceuticals Ltd, Adeshwar Meditex Ltd, Docmode Health Technologies Ltd.
Valuation & Returns
At ₹25.3 a share, Vanta Bioscience Ltd (VANTABIO) was valued at a price-to-earnings ratio of 163.55x against an industry P/E of 61.73x and a price-to-book of 0.85x on a book value of ₹29.77 per share. Solomo computes return on equity of 0.51% and return on capital employed of 1.31% from filed results.
- P/E
- 163.55x
- Industry P/E
- 61.73x
- P/B
- 0.85x
- EPS (TTM)
- ₹-7.56
- Book value / share
- ₹29.77
- ROE
- 0.51%
- ROCE
- 1.31%
- ROA
- 0.17%
- Debt / equity
- 1.8x
- Dividend yield
- 0%
- EBITDA margin
- 65.19%
- 52-week range
- ₹14.71 – ₹31.33
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vanta Bioscience Ltd (VANTABIO) reported revenue of ₹1.82 crore, net profit of ₹0.11 crore and earnings per share of ₹0.15. That compares with revenue of ₹1.96 crore and net profit of ₹-13.29 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1.51 crore and net profit ₹1.93 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 9.4 | 5.83 | 9.72 | 1.96 | 1.82 |
| Net profit (₹ cr) | 0.14 | -10.44 | -8.61 | -13.29 | 0.11 |
| EPS (₹) | 0.14 | -10.27 | -3.68 | -7.56 | 0.15 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -39.68% | -50.60% | -79.84% |
| Profit growth | - | - | -54.36% |
| Stock price CAGR | -30% | -18% | -13% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 72.81% of Vanta Bioscience Ltd (VANTABIO). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 72.81% | - | - | - | 27.19% |
| Sep 2025 | 72.81% | - | - | - | 27.19% |
| Mar 2025 | 69.36% | - | - | - | 30.64% |
| Sep 2024 | 69.36% | - | - | - | 30.64% |
| Mar 2024 | 69.36% | - | - | - | 30.64% |
| Sep 2023 | 69.36% | - | - | - | 30.64% |
| Mar 2023 | 69.36% | - | - | - | 30.64% |
| Sep 2022 | 69.36% | - | - | - | 30.64% |